These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20560971)

  • 1. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
    Wang X; Sinn AL; Pollok K; Sandusky G; Zhang S; Chen L; Liang J; Crean CD; Suvannasankha A; Abonour R; Sidor C; Bray MR; Farag SS
    Br J Haematol; 2010 Aug; 150(3):313-25. PubMed ID: 20560971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.
    Zhang S; Suvannasankha A; Crean CD; White VL; Johnson A; Chen CS; Farag SS
    Clin Cancer Res; 2007 Aug; 13(16):4750-8. PubMed ID: 17699852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
    Evans RP; Naber C; Steffler T; Checkland T; Maxwell CA; Keats JJ; Belch AR; Pilarski LM; Lai R; Reiman T
    Br J Haematol; 2008 Feb; 140(3):295-302. PubMed ID: 18076711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Killing effect of aurora kinase inhibitor ENMD-2076 on acute myelogenous leukemia cells].
    Cao H; Li M; Qian WB
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):479-84. PubMed ID: 23086638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action.
    Fletcher GC; Brokx RD; Denny TA; Hembrough TA; Plum SM; Fogler WE; Sidor CF; Bray MR
    Mol Cancer Ther; 2011 Jan; 10(1):126-37. PubMed ID: 21177375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
    Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma.
    Dingli D; Timm M; Russell SJ; Witzig TE; Rajkumar SV
    Clin Cancer Res; 2002 Dec; 8(12):3948-54. PubMed ID: 12473611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma.
    Zhang S; Farag SS
    Expert Opin Investig Drugs; 2011 Jul; 20(7):1015-28. PubMed ID: 21615212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways.
    Zhang YW; Jiang XX; Chen QS; Shi WY; Wang L; Sun HD; Shen ZX; Chen Z; Chen SJ; Zhao WL
    Exp Hematol; 2010 Mar; 38(3):191-201. PubMed ID: 20045442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Furano-1,2-naphthoquinone inhibits EGFR signaling associated with G2/M cell cycle arrest and apoptosis in A549 cells.
    Su JC; Lin KL; Chien CM; Tseng CH; Chen YL; Chang LS; Lin SR
    Cell Biochem Funct; 2010 Dec; 28(8):695-705. PubMed ID: 21104938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
    Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P
    Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
    Hideshima T; Catley L; Raje N; Chauhan D; Podar K; Mitsiades C; Tai YT; Vallet S; Kiziltepe T; Ocio E; Ikeda H; Okawa Y; Hideshima H; Munshi NC; Yasui H; Richardson PG; Anderson KC
    Br J Haematol; 2007 Sep; 138(6):783-91. PubMed ID: 17760810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.
    Diamond JR; Eckhardt SG; Tan AC; Newton TP; Selby HM; Brunkow KL; Kachaeva MI; Varella-Garcia M; Pitts TM; Bray MR; Fletcher GC; Tentler JJ
    Clin Cancer Res; 2013 Jan; 19(1):291-303. PubMed ID: 23136197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
    Gojo I; Zhang B; Fenton RG
    Clin Cancer Res; 2002 Nov; 8(11):3527-38. PubMed ID: 12429644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.